Related Experiment Video
Updated: Mar 6, 2026
A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
Published on: January 27, 2026
Targeting of protein translation as a new treatment paradigm for prostate cancer
Vidya P Ramamurthy1, Senthilmurugan Ramalingam, Andrew K Kwegyir-Afful
1aDepartment of Pharmacology bCenter for Biomolecular Therapeutics cMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine dVeterans Affairs Medical Center, Baltimore, Maryland, USA.
Purpose Of Review:
The current overview will summarize some of the developments in the area of protein translation, including their relation to the therapeutic targeting of prostate cancer.
Recent Findings:
Translational control, mediated by the rate-limiting eukaryotic translation initiation factor 4E (eIF4E), drives selective translation of several oncogenic proteins, thereby contributing to tumor growth, metastasis, and treatment resistance in various cancers, including prostate cancer. As an essential regulatory hub, several oncogenic hyperactive signaling pathways appear to converge on eIF4E to promote tumorigenesis. Several approaches that target the eIF4E-dependent protein translation network are being actively studied, and it is likely that some may ultimately emerge as promising anticancer therapeutics.
Summary:
An array of inhibitors has shown promise in targeting specific components of the translational machinery in several preclinical models of prostate cancer. It is hoped that some of these approaches may ultimately have relevance in improving the clinical outcomes of patients with advanced prostate cancer.
Insights
Targeting protein translation, specifically eukaryotic translation initiation factor 4E (eIF4E), shows promise for treating prostate cancer. Inhibitors targeting this pathway may offer new therapeutic options for advanced disease.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Translational control is crucial in cancer development.
- eIF4E is a key regulator of protein translation and oncogenesis.
Purpose of the Study:
- To review developments in protein translation.
- To explore therapeutic targeting of protein translation in prostate cancer.
Main Methods:
- Review of current research on translational control.
- Analysis of eIF4E-dependent pathways in cancer.
Main Results:
- eIF4E mediates selective translation of oncogenic proteins, promoting tumor growth and resistance.
- Targeting the eIF4E network is under investigation as a therapeutic strategy.
- Preclinical models show promise for inhibitors of the translational machinery.
Conclusions:
- Inhibitors targeting protein translation components show potential in preclinical prostate cancer models.
- These strategies may improve outcomes for patients with advanced prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:31Translation
Translation Produces the Building Blocks of Life
Proteins are...
01:34Directing Proteins to the Rough Endoplasmic Reticulum
01:29Translation in Prokaryotes
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...